These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32361027)

  • 1. Revisiting aminocoumarins for the treatment of melioidosis.
    Willcocks SJ; Cia F; Francisco AF; Wren BW
    Int J Antimicrob Agents; 2020 Jul; 56(1):106002. PubMed ID: 32361027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocin.
    Schmutz E; Mühlenweg A; Li SM; Heide L
    Antimicrob Agents Chemother; 2003 Mar; 47(3):869-77. PubMed ID: 12604514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
    Feterl M; Govan B; Engler C; Norton R; Ketheesan N
    Int J Antimicrob Agents; 2006 Nov; 28(5):460-4. PubMed ID: 17046208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Resistance to Folate Pathway Inhibitors in
    Podnecky NL; Rhodes KA; Mima T; Drew HR; Chirakul S; Wuthiekanun V; Schupp JM; Sarovich DS; Currie BJ; Keim P; Schweizer HP
    mBio; 2017 Sep; 8(5):. PubMed ID: 28874476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.
    Hooper DC; Wolfson JS; McHugh GL; Winters MB; Swartz MN
    Antimicrob Agents Chemother; 1982 Oct; 22(4):662-71. PubMed ID: 6295263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model.
    Ulett GC; Norton RE; Hirst RG
    Pathology; 1999 Aug; 31(3):264-7. PubMed ID: 10503275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of repurposing chloroquine as an adjunct therapy for melioidosis based on a murine model of Burkholderia pseudomallei infection.
    Ganesan N; Embi N; Hasidah MS
    Trop Biomed; 2020 Jun; 37(2):303-317. PubMed ID: 33612800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic, and synthetic approach.
    Galm U; Dessoy MA; Schmidt J; Wessjohann LA; Heide L
    Chem Biol; 2004 Feb; 11(2):173-83. PubMed ID: 15123279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
    Propst KL; Troyer RM; Kellihan LM; Schweizer HP; Dow SW
    Antimicrob Agents Chemother; 2010 May; 54(5):1785-92. PubMed ID: 20176901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary Delivery of Ceftazidime for the Treatment of Melioidosis in a Murine Model.
    Ruiz SI; Bowen LE; Bailey MM; Berkland C
    Mol Pharm; 2018 Mar; 15(3):1371-1376. PubMed ID: 29363975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics and function of the capsules of Burkholderia pseudomallei and their potential as therapeutic targets.
    Reckseidler-Zenteno SL; Moore R; Woods DE
    Mini Rev Med Chem; 2009 Feb; 9(2):265-71. PubMed ID: 19200030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidyl-Prolyl Isomerase
    Bzdyl NM; Scott NE; Norville IH; Scott AE; Atkins T; Pang S; Sarovich DS; Coombs G; Inglis TJJ; Kahler CM; Sarkar-Tyson M
    Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331957
    [No Abstract]   [Full Text] [Related]  

  • 13. An in situ high-throughput screen identifies inhibitors of intracellular
    Bulterys PL; Toesca IJ; Norris MH; Maloy JP; Fitz-Gibbon ST; France B; Toffig B; Morselli M; Somprasong N; Pellegrini M; Schweizer HP; Tuanyok A; Damoiseaux R; French CT; Miller JF
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18597-18606. PubMed ID: 31439817
    [No Abstract]   [Full Text] [Related]  

  • 14. New aminocoumarin antibiotics as gyrase inhibitors.
    Heide L
    Int J Med Microbiol; 2014 Jan; 304(1):31-6. PubMed ID: 24079980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic resistance in Burkholderia species.
    Rhodes KA; Schweizer HP
    Drug Resist Updat; 2016 Sep; 28():82-90. PubMed ID: 27620956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cloning and sequence analysis of the clorobiocin biosynthetic gene cluster: new insights into the biosynthesis of aminocoumarin antibiotics.
    Pojer F; Li SM; Heide L
    Microbiology (Reading); 2002 Dec; 148(Pt 12):3901-3911. PubMed ID: 12480894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependant acute or subacute disease caused by Burkholderia pseudomallei strain NCTC 13392 in a BALB/c aerosol model of infection.
    Funnell SGP; Tree JA; Hatch GJ; Bate SR; Hall G; Pearson G; Rayner EL; Roberts ADG; Vipond J
    J Appl Microbiol; 2019 Oct; 127(4):1224-1235. PubMed ID: 31330088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of Burkholderia pseudomallei isolates in Northern Vietnam.
    Nhung PH; Van VH; Anh NQ; Phuong DM
    J Glob Antimicrob Resist; 2019 Sep; 18():34-36. PubMed ID: 30685463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a novel whole animal HTS technology platform for melioidosis drug discovery.
    Lakshmanan U; Yap A; Fulwood J; Yichun L; Hoon SS; Lim J; Ting A; Sem XH; Kreisberg JF; Tan P; Tan G; Flotow H
    Comb Chem High Throughput Screen; 2014; 17(9):790-803. PubMed ID: 25329838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis.
    Leakey AK; Ulett GC; Hirst RG
    Microb Pathog; 1998 May; 24(5):269-75. PubMed ID: 9600859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.